Outcomes of salvage high dose-rate brachytherapy with or without pelvic external beam radiotherapy in patients with palpable local recurrence of prostate cancer after radical prostatectomy

Published:January 07, 2023DOI:



      This study aims to evaluate the outcomes and toxicities in patients with palpable local recurrence of prostate cancer after radical prostatectomy (RP), who were treated with salvage high dose-rate brachytherapy (HDR-BT) with or without pelvic external beam radiotherapy (EBRT).


      This retrospective review included patients with palpable local recurrence of prostate cancer after RP who underwent salvage HDR-BT at a single institution between 2002 and 2020. HDR-BT regimens included 950 cGy x 2 (N = 4) or 1500 cGy x 1 (N = 2) combined with EBRT; or monotherapy with 950 cGy x 4 (N = 1) or 800 cGy x 2 (N = 1). Toxicity was graded according to CTCAE Version 5.0.


      A total of 8 patients were included. Median follow-up was 49 months (range: 9–223 months). Median age at time of salvage brachytherapy was 68 years (range: 59–85 years). Seven out of 8 patients were alive at last follow-up. There have been no locoregional recurrences. Three patients developed distant metastatic disease. One patient developed acute grade 3 urinary obstruction requiring catheterization, which lasted for 1 day postbrachytherapy. One patient developed late grade 3 urinary incontinence 18 months after brachytherapy. There were no other grade 2+ toxicities.


      This study demonstrates the safety and efficacy of salvage HDR-BT in the setting of palpable local recurrence of prostate cancer after RP, with durable locoregional control and acceptable rates of toxicity. HDR-BT should be further explored as an option for dose-escalated salvage radiotherapy after prior radical prostatectomy.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel RL
        • Miller KD
        • Fuchs HE
        • et al.
        Cancer statistics.
        Cancer J Clin. 2021; 71 (2021): 7-33
        • Thompson IM
        • Valicenti RK
        • Albertsen P
        • et al.
        Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline.
        J Urol. 2013; 190: 441-449
        • Pound CR
        • Partin AW
        • Eisenberger MA
        • et al.
        Natural history of progression after PSA elevation following radical prostatectomy.
        JAMA. 1999; 281: 1591-1597
        • Lange PH
        • Ercole CJ
        • Lightner DJ
        • et al.
        The value of serum prostate specific antigen determinations before and after radical prostatectomy.
        J Urol. 1989; 141: 873-879
        • Pisansky TM
        • Kozelsky TF
        • Myers RP
        • et al.
        Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer.
        J Urol. 2000; 163: 845-850
        • Pisansky TM
        • Thompson IM
        • Valicenti RK
        • et al.
        Adjuvant and salvage radiotherapy after prostatectomy: ASTRO/AUA guideline amendment 2018-2019.
        J Urol. 2019; 202: 533-538
        • Pollack A
        • Karrison TG
        • Balogh AG
        • et al.
        The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
        Lancet. 2022; 399: 1886-1901
        • Parzen JS
        • Ye H
        • Gustafson G
        • et al.
        Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer.
        Radiother Oncol. 2020; 147: 123-129
        • Matta R
        • Chapple CR
        • Fisch M
        • et al.
        Pelvic complications after prostate cancer radiation therapy and their management: An International Collaborative Narrative Review.
        Eur Urol. 2019; 75: 464-476
        • Grills IS
        • Martinez AA
        • Hollander M
        • et al.
        High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
        J Urol. 2004; 171: 1098-1104
        • Hauswald H
        • Kamrava MR
        • Fallon JM
        • et al.
        High-dose-rate monotherapy for localized prostate cancer: 10-year results.
        Int J Radiat Oncol*Biol*Phys. 2016; 94: 667-674
        • Morton G
        • McGuffin M
        • Chung HT
        • et al.
        Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy.
        Radiother Oncol. 2020; 146: 90-96
        • Clinically Localized Prostate Cancer
        AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options.
        Journal of Urology. Accessed. March 14, 2022; (|)
        • Sanda MG
        • Cadeddu JA
        • Kirkby E
        • et al.
        Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline. Part II: recommended approaches and details of specific care options.
        J Urol. 2018; 199: 990-997
        • Hoskin PJ
        • Rojas AM
        • Bownes PJ
        • et al.
        Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.
        Radiother Oncol. 2012; 103: 217-222
        • Joseph D
        • Denham JW
        • Steigler A
        • et al.
        Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR trial.
        Int J Radiat Oncol Biol Phys. 2020; 106: 693-702
        • Hsu IC
        • Rodgers JP
        • Shinohara K
        • et al.
        Long-term results of NRG oncology/RTOG 0321: a phase II trial of combined high dose rate brachytherapy and external beam radiation therapy for adenocarcinoma of the prostate.
        Int J Radiat Oncol*Biol*Phys. 2021; 110: 700-707
        • Buchser D
        • Gomez-Iturriaga A
        • Melcon JIR
        • et al.
        Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy.
        J Contemp Brachyther. 2016; 8: 477-483
        • Macdonald OK
        • Schild SE
        • Vora SA
        • et al.
        Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy.
        Int J Radiat Oncol Biol Phys. 2004; 58: 1530-1535
        • Strom TJ
        • Wilder RB
        • Fernandez DC
        • et al.
        High-dose-rate brachytherapy with or without intensity modulated radiation therapy as salvage treatment for an isolated, gross local recurrence of prostate cancer post-prostatectomy.
        Brachytherapy. 2014; 13: 123-127
        • Cookson MS
        • Aus G
        • Burnett AL
        • et al.
        Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes.
        J Urol. 2007; 177: 540-545
        • Raleigh DR
        • Chang AJ
        • Tomlin B
        • et al.
        Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer.
        Brachytherapy. 2015; 14: 795-800
        • Xu MJ
        • Chen KS
        • Chang AJ
        • et al.
        Single-fraction brachytherapy as monotherapy for early-stage prostate cancer: The UCSF experience.
        Brachytherapy. 2019; 18: 470-476
        • Kneebone A
        • Fraser-Browne C
        • Duchesne GM
        • et al.
        Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
        Lancet Oncol. 2020; 21: 1331-1340
        • Parker CC
        • Clarke NW
        • Cook AD
        • et al.
        Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.
        Lancet. 2020; 0
        • Sargos P
        • Chabaud S
        • Latorzeff I
        • et al.
        Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.
        Lancet Oncol. 2020; 21: 1341-1352
        • Vale CL
        • Fisher D
        • Kneebone A
        • et al.
        Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.
        Lancet. 2020; 396: 1422-1431
        • Zaine H
        • Vandendorpe B
        • Bataille B
        • et al.
        Salvage radiotherapy for macroscopic local recurrence following radical prostatectomy.
        Front Oncol. 2021; 11669261
        • Vogel MME
        • Dewes S
        • Sage EK
        • et al.
        Feasibility and outcome of PSMA-PET-based dose-escalated salvage radiotherapy versus conventional salvage radiotherapy for patients with recurrent prostate cancer.
        Front Oncol. 2021; 11715020
        • Niehoff P
        • Loch T
        • Nürnberg N
        • et al.
        Feasibility and preliminary outcome of salvage combined HDR brachytherapy and external beam radiotherapy (EBRT) for local recurrences after radical prostatectomy.
        Brachytherapy. 2005; 4: 141-145
        • Jani AB
        • Schreibmann E
        • Goyal S
        • et al.
        18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
        Lancet. 2021; 397: 1895-1904
        • Fendler WP
        • Calais J
        • Eiber M
        • et al.
        Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial.
        JAMA Oncol. 2019; 5: 856-863
        • Boreta L
        • Gadzinski AJ
        • Wu SY
        • et al.
        Location of recurrence by Gallium-68 PSMA-11 PET scan in prostate cancer patients eligible for salvage radiotherapy.
        Urology. 2019; 129: 165-171
        • Stephenson AJ
        • Scardino PT
        • Kattan MW
        • et al.
        Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
        J Clin Oncol. 2007; 25: 2035-2041
        • King CR.
        The timing of salvage radiotherapy after radical prostatectomy: a systematic review.
        Int J Radiat Oncol*Biol*Phys. 2012; 84: 104-111